Please take a moment and listen to the introductory video on your left. Then, view the video below and follow the instructions for the quiz.

The video below from the Psychedelic Science in the 21st Century is available for continuing education credit through the co-sponsorhip of the Mulitdisciplinary Association for Psychedelic Studies and the Spiritual Competency Resource Center for many physicians, psychologists, social workers, MFTs, nurses and other healthcare professionals.


    1. Watch the video on your left. There is no charge for viewing the video
    2. Answer the questions below.
    3. When finished, press the Score My Quiz button. After that you will have an option to checkout and print your CE certificate.*
    4. To view CE information click here

Charles Grob, M.D., Alicia Danforth, MA Harbor-UCLA Study of Psilocybin Treatment for Anxiety in Advanced-Stage Cancer Patients

Course Presenter(s):
Author(s): Charles Grob, M.D. | Alicia Danforth, Ph.D. | (click author name for biography)

Course Description: Dr. Grob discusses a completed, randomized, double-blind, placebo-controlled study of psilocybin-assisted psychotherapy in subjects with anxiety associated with cancer. His talk also covers the psychobiologic effects of MDMA in humans, the MDMA-neurotoxicity controversy, the effects of MDMA on cerebral blood flow, and the neuropsychological effects of MDMA in recreational users. A graduate student of clinical psychology and a research associate and co-facilitator for the Harbor-UCLA cancer anxiety trial with psilocybin, Alicia Danforth provides an overview of the research from the late 1950s through the early 1970s on the use of LSD and psilocybin in the treatment of severe autism in children. She also discusses the potential use of MDMA-assisted therapy as a supplement to treatment for individuals with high-functioning autism and Asperger’s syndrome.
Biography of Presenters:

Charles S. Grob, M.D
., is the Director of the Division of Child and Adolescent Psychiatry at Harbor-UCLA Medical Center, and Professor of Psychiatry and Pediatrics at the UCLA School of Medicine. He conducted the first government-approved psychobiological research study of MDMA, and was the principal investigator of an international biomedical- psychiatric research project in the Brazilian Amazon of the plant hallucinogen ayahuasca. Over the last several years he has conducted a comprehensive research assessment of the safety and efficacy of psilocybin in the treatment of advanced-cancer patients with existential anxiety. Dr. Grob is the editor of Hallucinogens: A Reader (Tarcher/ Putnam, 2002) and the co-editor (with Roger Walsh) of Higher Wisdom: Eminent Elders Explore the Continuing Impact of Psychedelics (SUNY Press, 2005). He has published numerous articles in medical and psychiatric journal and collected volumes. He is a founding board member of the Heffter Research Institute.

Alicia Danforth, Ph.D
. candidate, is a clinical psychedelic re- searcher and writer. Since 2006, she has coordinated and co- facilitated treatment sessions for Dr. Charles Grob’s Harbor-UCLA cancer anxiety trial with psilocybin. She also oversees a nationwide web-based recruitment effort for a similar trial currently underway at the Johns Hopkins School of Medicine. Inspired by the results of this work, Alicia began a Ph.D. program in Clinical Psychology at the Institute of Transpersonal Psychology (ITP) in Palo Alto. She was a speaker on the Rising Researchers panel at the World Psychedelic Forum in 2008. She has also given talks and workshops related to her research and the broader psychedelic community at Burning Man, Horizons, Symbiosis, and the Women’s Visionary Council Salon. She also published an original manuscript on using Focusing-oriented psychotherapy techniques as part of preparation for psychedelic therapy sessions in the spring, 2010, edition of the Journal of Transpersonal Psychology.

Date of original release: April 18, 2010
Termination date (date after which enduring material is no longer certified for credit): April 17, 2012

Charles Grob, M.D. & Alicia Danforth, Ph.D. student, Cancer/Psilocybin from MAPS: Psychedelic Science on Vimeo.

True/False Comprehension Quiz

The chemical structure of psilocybin is similar to the neurotransmitter serotonin.
The effects of a medium dose of psilocybin usually last between 4 – 6 hours.
Over 40,000 individuals have received hallucinogens in clinical and other research settings.
Only about 3% of patients with terminal cancer in a 1973 study (Grof, et al.) showed dramatic improvement after LSD-assisted psychotherapy.
A recent research study has shown that psilocybin use often induces mystical experiences in healthy individuals.

Rate this Course:
Rating of this course out of 7 votes:28%


Spiritual Competency Resource Center Website